181 related articles for article (PubMed ID: 21967521)
1. Antisense oligonucleotide induced dystrophin exon 45 skipping at a low half-maximal effective concentration in a cell-free splicing system.
Malueka RG; Yagi M; Awano H; Lee T; Dwianingsih EK; Nishida A; Takeshima Y; Matsuo M
Nucleic Acid Ther; 2011 Oct; 21(5):347-53. PubMed ID: 21967521
[TBL] [Abstract][Full Text] [Related]
2. Phosphorothioate modification of chimeric 2ยด-O-methyl RNA/ethylene-bridged nucleic acid oligonucleotides increases dystrophin exon 45 skipping capability and reduces cytotoxicity.
Malueka RG; Dwianingsih EK; Yagi M; Lee T; Nishida A; Iijima K; Takeshima Y; Matsuo M
Kobe J Med Sci; 2015 Feb; 60(4):E86-94. PubMed ID: 25791417
[TBL] [Abstract][Full Text] [Related]
3. 2'-O-Methyl RNA/Ethylene-Bridged Nucleic Acid Chimera Antisense Oligonucleotides to Induce Dystrophin Exon 45 Skipping.
Lee T; Awano H; Yagi M; Matsumoto M; Watanabe N; Goda R; Koizumi M; Takeshima Y; Matsuo M
Genes (Basel); 2017 Feb; 8(2):. PubMed ID: 28208626
[TBL] [Abstract][Full Text] [Related]
4. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD
Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
[TBL] [Abstract][Full Text] [Related]
5. Optimizing RNA/ENA chimeric antisense oligonucleotides using in vitro splicing.
Takeshima Y; Yagi M; Matsuo M
Methods Mol Biol; 2012; 867():131-41. PubMed ID: 22454059
[TBL] [Abstract][Full Text] [Related]
6. Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries.
Adams AM; Harding PL; Iversen PL; Coleman C; Fletcher S; Wilton SD
BMC Mol Biol; 2007 Jul; 8():57. PubMed ID: 17601349
[TBL] [Abstract][Full Text] [Related]
7. Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene.
Errington SJ; Mann CJ; Fletcher S; Wilton SD
J Gene Med; 2003 Jun; 5(6):518-27. PubMed ID: 12797117
[TBL] [Abstract][Full Text] [Related]
8. Chimeric RNA/ethylene-bridged nucleic acids promote dystrophin expression in myocytes of duchenne muscular dystrophy by inducing skipping of the nonsense mutation-encoding exon.
Surono A; Van Khanh T; Takeshima Y; Wada H; Yagi M; Takagi M; Koizumi M; Matsuo M
Hum Gene Ther; 2004 Aug; 15(8):749-57. PubMed ID: 15319032
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle.
Arechavala-Gomeza V; Graham IR; Popplewell LJ; Adams AM; Aartsma-Rus A; Kinali M; Morgan JE; van Deutekom JC; Wilton SD; Dickson G; Muntoni F
Hum Gene Ther; 2007 Sep; 18(9):798-810. PubMed ID: 17767400
[TBL] [Abstract][Full Text] [Related]
10. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays.
Graham IR; Hill VJ; Manoharan M; Inamati GB; Dickson G
J Gene Med; 2004 Oct; 6(10):1149-58. PubMed ID: 15386737
[TBL] [Abstract][Full Text] [Related]
11. Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe.
Takeshima Y; Nishio H; Sakamoto H; Nakamura H; Matsuo M
J Clin Invest; 1995 Feb; 95(2):515-20. PubMed ID: 7860733
[TBL] [Abstract][Full Text] [Related]
12. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
Echigoya Y; Yokota T
Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
[TBL] [Abstract][Full Text] [Related]
13. Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle.
Popplewell LJ; Graham IR; Malerba A; Dickson G
Methods Mol Biol; 2011; 709():153-78. PubMed ID: 21194027
[TBL] [Abstract][Full Text] [Related]
14. Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers.
Popplewell LJ; Malerba A; Dickson G
Methods Mol Biol; 2012; 867():143-67. PubMed ID: 22454060
[TBL] [Abstract][Full Text] [Related]
15. Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy.
Mann CJ; Honeyman K; McClorey G; Fletcher S; Wilton SD
J Gene Med; 2002; 4(6):644-54. PubMed ID: 12439856
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal administration of phosphorothioate antisense oligodeoxynucleotide against splicing enhancer sequence induced exon skipping in dystrophin mRNA expressed in mdx skeletal muscle.
Takeshima Y; Yagi M; Wada H; Matsuo M
Brain Dev; 2005 Oct; 27(7):488-93. PubMed ID: 16198206
[TBL] [Abstract][Full Text] [Related]
17. Efficient Skipping of Single Exon Duplications in DMD Patient-Derived Cell Lines Using an Antisense Oligonucleotide Approach.
Wein N; Vulin A; Findlay AR; Gumienny F; Huang N; Wilton SD; Flanigan KM
J Neuromuscul Dis; 2017; 4(3):199-207. PubMed ID: 28869484
[TBL] [Abstract][Full Text] [Related]
18. Induced dystrophin exon skipping in human muscle explants.
McClorey G; Fall AM; Moulton HM; Iversen PL; Rasko JE; Ryan M; Fletcher S; Wilton SD
Neuromuscul Disord; 2006 Oct; 16(9-10):583-90. PubMed ID: 16919955
[TBL] [Abstract][Full Text] [Related]
19. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
[TBL] [Abstract][Full Text] [Related]
20. Systematic evaluation of 2'-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro.
Chen S; Le BT; Chakravarthy M; Kosbar TR; Veedu RN
Sci Rep; 2019 Apr; 9(1):6078. PubMed ID: 30988454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
